Founded more than 30 years ago, we have long believed we have a unique opportunity to champion underserved patient communities. Today, as the global leader in rare diseases, we are determined to build on this position as we go forward.
Speed matters, especially to the patients who are waiting for treatments and diagnosis. As we grow, we want to retain the spirit of a small biotech with the benefits of both scale and agility. We do that through flat and rapid decision-making and operational excellence with the interplay among our key strategic centers in Boston, Dublin and Zug. Through a fast-paced, entrepreneurial and international culture, we give people freedom and opportunity to excel while also setting a high bar for ethics and responsibility.